Tick-borne viral encephalitis
ICD-10 A84 is a billable code used to indicate a diagnosis of tick-borne viral encephalitis.
Tick-borne viral encephalitis (TBE) is a viral infection that affects the central nervous system, primarily transmitted through the bite of infected ticks, particularly the Ixodes ricinus and Ixodes persulcatus species. The disease is endemic in various regions of Europe and Asia, where it poses a significant public health risk. Clinically, TBE can present in three stages: an initial phase characterized by flu-like symptoms such as fever, headache, and fatigue; a second phase where neurological symptoms may develop, including meningitis, encephalitis, or myelitis; and a potential third phase that can lead to severe neurological complications such as seizures, paralysis, or cognitive impairment. Diagnosis is typically confirmed through serological testing for specific antibodies against the TBE virus. Vaccination is available and recommended for individuals at high risk, such as those living in endemic areas or engaging in outdoor activities in these regions. Understanding the clinical presentation, potential complications, and vaccination status is crucial for effective management and coding of this condition.
Detailed history of exposure, vaccination status, and clinical symptoms.
Patients presenting with fever and neurological symptoms after tick exposure.
Ensure serological test results are included in the documentation.
Comprehensive neurological examination findings and imaging results.
Patients with severe neurological deficits following a tick bite.
Document all neurological assessments and any complications.
Used to confirm diagnosis in patients presenting with neurological symptoms after tick exposure.
Document the reason for testing and clinical symptoms.
Infectious disease specialists should ensure comprehensive documentation of exposure history.
Common symptoms include fever, headache, fatigue, and in severe cases, neurological symptoms such as confusion, seizures, and paralysis.
Yes, a vaccine is available and is recommended for individuals at high risk, particularly those living in endemic areas.
